Literature DB >> 11240733

Options for modulation of drug resistance in ovarian cancer.

H. J. G. Arts1, A. G. J. Van Der Zee, S. De Jong, E. G. E. De Vries.   

Abstract

The objective of this paper is to present an update of mechanisms responsible for drug resistance in ovarian cancer and the possible therapeutic options to modulate this resistance using literature review with emphasis on data acquired in studies comprising ovarian tumor samples. The classic concepts on resistance in ovarian cancer, namely platinum and multidrug resistance, are briefly discussed, followed by a description of more recent insights concerning the role of apoptosis in the development of chemoresistance. A wide variety of mechanisms may be responsible for drug resistance in ovarian cancer. However, a growing body of evidence indicates that defects in the intra- and extracellular apoptotic pathways are an important cause of resistance to cytotoxic agents which opens several new treatment strategies.

Entities:  

Year:  2000        PMID: 11240733     DOI: 10.1046/j.1525-1438.2000.99511.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

1.  RSF1 is a positive regulator of NF-κB-induced gene expression required for ovarian cancer chemoresistance.

Authors:  Yeong-In Yang; Ji-Hye Ahn; Kyung-Tae Lee; Ie-Ming Shih; Jung-Hye Choi
Journal:  Cancer Res       Date:  2014-02-24       Impact factor: 12.701

2.  Assessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer.

Authors:  Vijayalakshmi N Ayyagari; Nancy A Johnston; Laurent Brard
Journal:  Anticancer Drugs       Date:  2016-07       Impact factor: 2.248

3.  miR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells.

Authors:  Ying Wang; Chenming Yan; Junxia Qi; Chunyan Liu; Juan Yu; Huabin Wang
Journal:  Mol Cell Biochem       Date:  2021-10-30       Impact factor: 3.396

4.  Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies.

Authors:  P de Graeff; J Hall; A P G Crijns; G H de Bock; J Paul; K A Oien; K A ten Hoor; S de Jong; H Hollema; J M S Bartlett; R Brown; A G J van der Zee
Journal:  Br J Cancer       Date:  2006-08-01       Impact factor: 7.640

5.  Inhibition of XIAP increases carboplatin sensitivity in ovarian cancer.

Authors:  Yiping Zhang; Furong Huang; Qingyu Luo; Xiaowei Wu; Zhihua Liu; Hongyan Chen; Yinghui Huang
Journal:  Onco Targets Ther       Date:  2018-12-05       Impact factor: 4.147

6.  Bithionol inhibits ovarian cancer cell growth in vitro - studies on mechanism(s) of action.

Authors:  Vijayalakshmi N Ayyagari; Laurent Brard
Journal:  BMC Cancer       Date:  2014-02-04       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.